Market Opportunity

A $4.3B+ Addressable Market

The ERT market is one of the largest and fastest-growing segments in rare disease therapeutics.

$10.4B
Global ERT market (2023)
$17B+
Projected by 2026
~9%
CAGR for next 10 years
75%+
ERT share of all LSD treatments

Target Markets

Pompe & Fabry Disease: Large, Growing, Underserved

Pompe Disease

$1.2B
US Market
$1.9B
Global Market

Sanofi (Lumizyme/Nexviazyme): Pompe franchise €316M in H1 2025. Nexviazyme growing 20%+ YoY.

Amicus (Pombiliti + Opfolda): ~$70.3M in 2024.

Key gap: limited efficacy in skeletal muscle and lung.

Fabry Disease

$1.4B
US Market
$2.4B
Global Market

Sanofi (Fabrazyme): ~$1.1B in 2024.

Takeda (Replagal): ~$514M in 2024.

Chiesi/Protalix (Elfabrio): ~$80M in 2023, growing rapidly.

Key gap: $800M+ kidney nephropathy underserved.

Competitive Edge

How Spell Stands Apart

5–10×

Best-in-Class Delivery

Higher enzyme uptake in hard-to-treat tissues: muscle, kidney, lung, heart.

$800M+

First-to-Treat

Spell-102 targets Fabry kidney nephropathy — a massive underserved segment no existing ERT addresses.

80–90%

Lower Costs

Reduction in enzyme manufacturing expense, enabling better margins and patient access.

Want to Learn More?

Get in touch to learn more about how Spell Therapeutics is positioned to transform the ERT landscape.

Contact Us